Enhanced hypercholesterolemia therapy: The ezetimibe/simvastatin tablet

Drugs of Today

Volumn 41, Issue 5, 2005, Pages 317-327

  Cole, Patrick ^b   Rabasseda, Xavier ^a  

^a Medical Information Department   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; CHOLESTEROL; EZETIMIBE; FLUINDOSTATIN; GEMFIBROZIL; GLIPIZIDE; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AREA UNDER THE CURVE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; HYPERCHOLESTEROLEMIA; MONOTHERAPY; NONHUMAN; REVIEW; SIDE EFFECT;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; DRUG COMBINATIONS; HUMANS; HYPERCHOLESTEROLEMIA; RANDOMIZED CONTROLLED TRIALS; SIMVASTATIN;

EID: 23044474349     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2005.41.5.893614     Document Type: Review

References (27)

1. Stein, E.A. Managing dyslipidemia in the high-risk patient. Am J Cardiol 2002, 89: 50C-57C.
2. Kastelein, J.J. The future of lipid-lowering therapy: The big picture. Neth J Med 2003, 61: 35-9.
3. Mark, L., Csaszar, A. Antilipemic agents in combined therapy. Orv Hetil 2002, 143: 1973-8.
4. Cheng, A.Y., Leiter, L.A. Clinical use of ezetimibe. Can J Clin Pharmacol 2003, 10 (Suppl. A):21A-25A.
5. Denke, M.A. Combination therapy. J Managed Care Pharmacy 2003, 9: 17-99.
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344: 1383-9.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002, 360: 7-22.
8. Farnier, M. Ezetimibe in hypercholesterolaemia. Int J Clin Pract 2002, 56: 611-4.
9. Davidson, M.H. Ezetimibe: A novel option for lowering cholesterol. Expert Rev Cardiovasc Ther 2003, 1: 11-21.
10. Lipka, L.J. Ezetimibe: A first-in-class, novel cholesterol absorption inhibitor. Cardiovasc Drug Rev 2003, 21: 293-312.
11. Jeu, L., Cheng, J.W. Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Clin Ther 2003, 25: 2352-87.
12. Davis, H.R. Jr., Pula, K.K., Alton, K.B., Burner, R.E., Watkins, R.W. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Metabolism 2001, 50: 1234-41.
13. Kosoglou, T., Meyer, I., Veltri, E.P. et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002, 54:309-19.
14. Gagné, C., Bays, H.E., Weiss, S.R. et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002, 90: 1084-91.
15. Pearson, T.A., Denke, M.A., McBride, P.E., Battisti, W.P., Brady, W.E., Palmisano, U.A. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005, 80: 587-95.
16. Ballantyne, C.M., Blazing, M.A., King, T.R., Brady, W.E., Palmisano, J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004, 93: 1487-94.
17. Ballantyne, C.M., Abate, N., Yuan, Z., King, T.R., Palmisano, J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005, 149(3): 464-73.
18. Davidson, M., McGarry, T., Bettis, R. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002, 40: 2125.
19. Sager, P.T., Melani, L., Lipka, L. et al. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003, 92: 1414-8.
20. Sager, P., Capece, R., Lipka, L. et al. Ezetimibe co-administered with simvastatin reduced C-reactive protein in a large cohort of hypercholesterolemic patients. 74th EAS Cong (April 17-20, Seville) 2004, Abstr. M.641.
21. Goldberg, A.C., Sapre, A., Liu, J., Capece, R., Mitchel, Y.B.; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: A randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004, 79: 620-9.
22. Feldman, T., Koren, M., Insull, W. Jr. et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004, 93: 1481-6.
23. Gagne, C., Gaudet, D., Bruckert, E.; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002, 105: 2469-75.
24. Bays, H.E., Ose, L., Fraser, N. et al. Ezetimibe Study Group. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004, 26(11): 1758-73.
25. Assman, G., Kannenberg, F., Weng, W. et al. Effects of ezetimibe, simvastatin, and ezetimibe-simvastatin on noncholesterol sterol. 53rd Ann Sci Sess Am Coll Cardiol (March 7-10, New Orleans) 2004, Abstr. 1008-183.
26. Gaudiani, L.M., Lewin, A., Meneghini, L. et al. Efficacy and safety of ezetimibe coadministered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes Metab 2005, 7(1): 88-97.
27. Denke, M.A., McBride, P., Pearson, T. et al. Ezetimibe added to statin therapy reduces LDL-C, TG and non-HDL-C and improves HDL-C in patients with diabetes and metabolic syndrome. 86th Ann Meet Endocr Soc (June 16-19, New Orleans) 2004, Abstr. OR53-4.